Your browser is no longer supported. Please, upgrade your browser.
CGEN Compugen Ltd. monthly Stock Chart
Compugen Ltd.
Index- P/E- EPS (ttm)-0.39 Insider Own12.00% Shs Outstand70.28M Perf Week18.90%
Market Cap938.69M Forward P/E- EPS next Y-0.51 Insider Trans0.00% Shs Float- Perf Month0.07%
Income-26.10M PEG- EPS next Q-0.11 Inst Own40.60% Short Float- Perf Quarter54.46%
Sales- P/S- EPS this Y-5.10% Inst Trans50.43% Short Ratio2.58 Perf Half Y175.14%
Book/sh1.62 P/B9.09 EPS next Y-16.30% ROA-35.90% Target Price19.60 Perf Year367.30%
Cash/sh- P/C- EPS next 5Y- ROE-46.10% 52W Range2.73 - 17.85 Perf YTD146.98%
Dividend- P/FCF- EPS past 5Y-13.10% ROI- 52W High-17.54% Beta2.78
Dividend %- Quick Ratio14.00 Sales past 5Y- Gross Margin- 52W Low439.19% ATR1.47
Employees61 Current Ratio14.00 Sales Q/Q- Oper. Margin- RSI (14)53.88 Volatility13.58% 11.09%
OptionableYes Debt/Eq0.00 EPS Q/Q27.60% Profit Margin- Rel Volume1.35 Prev Close17.12
ShortableYes LT Debt/Eq0.00 EarningsMay 06 BMO Payout- Avg Volume1.48M Price14.72
Recom1.60 SMA203.43% SMA5019.47% SMA20094.96% Volume1,997,294 Change-14.02%
May-26-20Resumed JMP Securities Mkt Outperform $18
May-13-20Initiated Stifel Buy $19
May-07-20Initiated SVB Leerink Outperform
Apr-22-20Initiated ROTH Capital Buy $28
Mar-24-20Initiated SunTrust Buy $16
Jan-16-20Initiated Cantor Fitzgerald Overweight $10
Mar-29-18Initiated Oppenheimer Outperform
Feb-01-16Resumed Oppenheimer Outperform
Oct-15-15Initiated FBR Capital Outperform $14
Apr-23-15Resumed Jefferies Buy $11
Apr-21-15Initiated Oppenheimer Outperform $11
Feb-07-14Initiated MLV & Co Buy $14
Dec-28-09Reiterated Cantor Fitzgerald Buy $5 → $12
Jul-29-09Initiated Cantor Fitzgerald Buy $6.50
Jun-01-20 07:00AM  
May-27-20 07:00AM  
May-20-20 07:02AM  
May-18-20 08:46AM  
May-13-20 09:48AM  
May-08-20 02:39PM  
May-06-20 10:00PM  
May-04-20 11:57AM  
Apr-30-20 12:00PM  
Apr-27-20 06:05AM  
Apr-24-20 10:50AM  
Apr-23-20 07:00AM  
Apr-22-20 08:22AM  
Apr-20-20 07:00AM  
Apr-14-20 07:00AM  
Apr-06-20 07:00AM  
Mar-17-20 07:00AM  
Mar-12-20 06:05AM  
Mar-11-20 04:01PM  
Mar-10-20 10:00AM  
Mar-09-20 07:10AM  
Feb-20-20 07:05AM  
Feb-10-20 07:58AM  
Feb-07-20 07:00AM  
Feb-04-20 07:00AM  
Jan-29-20 08:30AM  
Jan-16-20 07:47PM  
Jan-09-20 07:00AM  
Jan-08-20 07:00AM  
Dec-23-19 08:04PM  
Dec-20-19 07:00AM  
Dec-17-19 09:11AM  
Dec-12-19 11:56AM  
Dec-11-19 09:04AM  
Dec-03-19 12:00PM  
Nov-11-19 07:00AM  
Nov-06-19 08:30AM  
Nov-05-19 08:06AM  
Nov-04-19 07:00AM  
Oct-28-19 07:00AM  
Oct-12-19 09:28AM  
Oct-10-19 09:00AM  
Oct-02-19 07:00AM  
Sep-19-19 07:00AM  
Aug-28-19 12:52PM  
Aug-22-19 12:01PM  
Aug-14-19 12:18PM  
Aug-13-19 11:53AM  
Aug-08-19 11:20AM  
Aug-05-19 04:16PM  
Jul-22-19 07:00AM  
Jul-16-19 07:00AM  
Jul-02-19 07:00AM  
Jun-27-19 03:07PM  
Jun-26-19 09:00AM  
Jun-12-19 09:14AM  
Jun-03-19 07:00AM  
May-23-19 09:00AM  
May-22-19 07:00AM  
May-20-19 06:08PM  
May-06-19 07:00AM  
Apr-18-19 09:00AM  
Apr-03-19 07:00AM  
Mar-26-19 08:40AM  
Mar-12-19 07:46AM  
Mar-08-19 10:04AM  
Mar-07-19 09:09AM  
Mar-05-19 07:00AM  
Mar-01-19 07:00AM  
Feb-26-19 02:00AM  
Feb-14-19 07:00AM  
Jan-22-19 07:00AM  
Jan-16-19 07:07AM  
Jan-14-19 07:00AM  
Nov-23-18 08:20AM  
Nov-13-18 07:00AM  
Nov-07-18 08:20AM  
Nov-05-18 05:35AM  
Oct-24-18 07:15AM  
Oct-12-18 03:09PM  
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets, including T cell immune checkpoints and other early-stage immuno-oncology programs focusing on myeloid target. Its product pipeline consists of COM701, a therapeutic antibody that is in phase I clinical trials for PVRIG; BAY 1905254, a therapeutic antibody that is in phase I clinical trials for ILDR2; and COM902, a therapeutic immuno-oncology antibody for TIGIT program. Compugen Ltd. has a collaboration agreement with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and license agreement with MedImmune Limited for the development of bi-specific and multi-specific immuno-oncology antibody products. The company was incorporated in 1993 and is headquartered in Holon, Israel.